Asahi Kaisei Adr (AHKSY) Stock News

Asahi Kasei Pharma (OTC:AHKSY) has initiated a Phase III clinical trial for ART-123 (Recomodulin™) in Japan, targeting the prevention of chemotherapy-induced peripheral neuropathy (CIPN). The drug, already approved in Japan since 2008, showed promising results in Phase I and II studies for managing CIPN symptoms without interfering with chemotherapy treatments.

The Phase III study will evaluate ART-123's efficacy and safety in colorectal cancer patients receiving oxaliplatin-based chemotherapy. The trial addresses a significant unmet medical need, as there are currently no established effective treatments for CIPN prevention or treatment. The development aligns with Asahi Kasei's strategic focus on healthcare sector growth, with pharmaceuticals designated as a 'First Priority' area.

Asahi Kasei (AHKSY) has been awarded the 2025 Imperial Invention Prize for developing a groundbreaking nickel-coated absorption layer technology that significantly improves chlor-alkali electrolysis processes. The invention addresses a critical issue in electrode deterioration during process interruptions by eliminating the need for mechanical solutions to suppress reverse current. The technology has been successfully commercialized and implemented in over 160 plants across 30+ countries. This innovation is particularly significant as it combines both porosity and strength in the absorption layer, previously a challenging trade-off. The company's "DENKAI AS ONE" model, launched in Houston in 2024, offers comprehensive electrolyzer solutions. Asahi Kasei is now exploring the technology's potential application in green hydrogen production through alkaline water electrolysis.

Asahi Kasei has introduced the TA Series of Sunfort™ dry film photoresist, a strategic product for advanced semiconductor packaging used in AI servers. The new series enables ultra-high resolution with conventional stepper exposure and laser direct imaging (LDI) systems, allowing patterning with a resist width of 1.0 µm using LDI exposure in 4 µm pitch design. This innovation is part of Asahi Kasei's Electronics business, which expects a 25% increase in operating profit between fiscal 2024-2027. The TA Series overcomes traditional dry film limitations, offering advantages for panel-level processing while maintaining high resolution previously only achieved with liquid resist. The product specifically targets growing demand in AI, automotive, and IoT markets, with enhanced global support focusing on Asia and North America.

Asahi Kasei Microdevices (AHKSY) and Dirac have announced a strategic partnership to integrate Dirac's AudioIQ software solutions into AKM's automotive audio DSPs, including the flagship AK7709. The collaboration aims to enhance in-car audio quality while reducing tuning complexity. AKM, having shipped over 200 million audio DSP units in 20 years, will combine its proprietary technologies like Dynamic Sound Control with Dirac's smart acoustics software.

The partnership addresses growing demand for premium in-cabin experiences as vehicles become increasingly autonomous. Dirac's AudioIQ platform will be embedded into AKM's DSPs to deliver consistent, high-quality sound across all seats while minimizing manual calibration requirements. The companies plan to expand their collaboration for future AKM audio DSP generations.

Asahi Kasei Bioprocess America (AKBA) and PeptiSystems have formed an exclusive global partnership to streamline peptide manufacturing processes. Under this agreement, AKBA will become the exclusive OEM for peptide synthesis columns to PeptiSystems, which specializes in R&D, manufacturing, and supply of peptide and oligonucleotide therapeutic synthesis instruments.

The collaboration integrates AKBA's THESYS® ACS Ergo design columns, launched in 2024, with PeptiSystems' next-generation synthesizers. The THESYS® ACS Ergo design offers reduced batch changeover time while maintaining safety and quality standards. This partnership is part of AKBA's expansion strategy in the TIDES market and follows the recent operational launch of Asahi Kasei Life Sciences division.

Asahi Kasei (AHKSY) has been awarded the prestigious Okochi Memorial Prize for its innovative Microcrystalline Cellulose (MCC) Ceolus™ UF grade excipient used in pharmaceutical tablets. The product solves critical formulation challenges by providing both high compactibility and flowability, which has been a long-standing industry challenge. Made from natural pulp, Ceolus™ features a unique porous particle shape that enhances tablet productivity and API uniformity, particularly beneficial for low-dose API tablets and small-format tablets. Additionally, Asahi Kasei has addressed nitrosamine concerns by ensuring their MCC Ceolus™ products maintain nitrite levels of 0.1 ppm or less, responding to FDA and EMA guidance on reducing potential carcinogenic impurities in pharmaceuticals.

Asahi Kasei Microdevices (AHKSY) has launched the AP4413, a new series of ultra-low current power management ICs (PMICs) designed for energy harvesting applications. The PMICs feature an extremely low current consumption of 52 nA and come in four variants to match different rechargeable battery types. Mass production began in February 2025.

The AP4413 series, housed in a 3.0 × 3.0 × 0.37 mm HXQFN package, enables autonomous charging of small rechargeable batteries through energy harvesting for applications like remote controls, Bluetooth® trackers, and IoT sensors. The technology is particularly relevant in Europe, where Regulation (EU) 2023/1542 promotes the transition from disposable to rechargeable batteries.

The PMICs feature AKM's proprietary ultra-low current voltage monitoring system and can support system operation with an inline capacitor even when the battery is completely discharged.

Asahi Kasei Microdevices (AKM) and Silicon Austria Labs (SAL) have successfully demonstrated a proof of concept for integrating current sensors into power modules for electric vehicle applications. The innovation focuses on the development of EZ232L, a linear Hall IC for coreless current sensors, designed to enhance traction inverter efficiency in electric vehicles.

The technology addresses the growing market demand for compact, lightweight solutions with high-resolution current sensing in electric vehicle inverter systems. Traction inverters, which convert DC power from batteries to AC power for electric motors, require precise current sensing across various driving conditions.

Key benefits include:

• Enhanced energy efficiency
• Compact and lightweight design
• High-resolution current sensing
• Cost advantages for small-to-medium production

The companies will present their research findings at PCIM Europe 2025 in Nuremberg, Germany, starting May 6. This collaboration marks a significant advancement in power module technology for electric vehicle applications.

Asahi Kasei has appointed Ken Shinomiya as the new Leader of its Healthcare Sector, succeeding Richard Packer. Shinomiya, who currently serves as President of Asahi Kasei Life Science, brings significant experience including previous roles as Vice President of Strategy at ZOLL Medical and President of Asahi Kasei Medical.

Under Shinomiya's leadership, the life science business has expanded beyond Planova™ virus removal filters to include CRO testing services and the acquisition of Bionova Scientific's biologics CDMO business. The Healthcare Sector has seen substantial globalization since acquiring ZOLL Medical in 2012, with its headquarters moving to the U.S. in 2023.

The sector aims to grow its pharmaceutical, life science, and critical care businesses, targeting an operating income of ¥150 billion by 2030. The company's mission focuses on improving patient outcomes through innovative therapeutics and medical devices.